Otsuka Pharmaceutical Development & Commercialization, Inc.
$14.8M 4,515 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Swedish Orphan Biovitrum Ab
Swedish Orphan Biovitrum Ab reported $14,704,202.94 across General Payments, Research, and Ownership to 55 physicians and teaching hospitals across 299 transactions.
- $14.7M Top 10% payer
- All-tracks total
- 299 Above-median volume
- Transactions
- 55 Below-median reach
- Recipients
- +$53.2K
- General Payments vs PY2023
Swedish Orphan Biovitrum Ab reported $14,704,202.94 across all CMS Open Payments tracks (General + Research + Ownership) to 55 physicians and teaching hospitals in Program Year 2024 - ranking #128 of 1,925 reporting manufacturers (0.1% of the all-tracks industry total); General Payments alone were $276,441.22, averaging $267.3K per recipient.
How Swedish Orphan Biovitrum Ab's $14.7M all-tracks total breaks down
Swedish Orphan Biovitrum Ab's payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
40/100
Total payments
A
100/100
Transaction volume
F
12/100
Physician reach
F
10/100
Payment type diversity
F
37/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer swedish-orphan-biovitrum-ab Swedish Orphan Biovitrum Ab
$14.7M · #128/1,925 · 0.1% industry · PY2024
- TOT $14.7M
- RANK #128
- SHARE 0.1%
- TXN 299
- RCP 55
- CAT 3
- GEN $276.4K
- ΔGEN +$53.2K
- TOP1 10.8%
- PY 2024
Volume peers
Nearest volume peer: Otsuka Pharmaceutical Development & Commercialization, Inc. ($14.8M)
Swedish Orphan Biovitrum Ab sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Swedish Orphan Biovitrum Ab's CMS-reported General Payments increased by $53.2K (+23.8%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: SWEDISH ORPHAN BIOVITRUM ABPY2023: SWEDISH ORPHAN BIOVITRUM ABPY2024: SWEDISH ORPHAN BIOVITRUM AB. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $223,280.50
- PY2024
- $276,441.22
What the Data Shows for Swedish Orphan Biovitrum Ab
CMS Open Payments is not a single ledger: the all-tracks total shown above is General Payments plus Research Payments plus Ownership/Investment interests, each with its own disclosure rules. For Swedish Orphan Biovitrum Ab, that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. Data for a given Program Year arrives roughly a year after the period it covers; our methodology page documents the release cadence and how we standardize the tracks for cross-company comparison.
Of the 3 general-payment categories charted below, "Travel and Lodging" is the largest at $135.7K across 15 transactions, 49.1% of this company's General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
"Travel and Lodging" leads Swedish Orphan Biovitrum Ab's 3-category general-payment breakdown at $135.7K, 49.1% of the reported total.
How Swedish Orphan Biovitrum Ab divides its payments
Top payment categories by total reported dollar volume
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Travel and Lodging | $135.7K | 15 | 49.1% |
| Consulting Fee | $111.9K | 31 | 40.5% |
| Compensation for Services Other Than Consulting | $28.9K | 9 | 10.4% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $125,218.48 (45.3%) of $276,441.22 in this company's General Payments records across 24 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Swedish Orphan Biovitrum Ab
The five named recipients with the highest reported General Payments from this company
- 1
Michael Tarantino
$29,820.09 across 2 reported transactions
- 2
Puja Khanna
$24,516.52 across 6 reported transactions
- 3
Edward Behrens
$24,215.38 across 3 reported transactions
- 4
Herbert Baraf
$24,111.16 across 5 reported transactions
- 5
Rachael Grace
$22,555.33 across 3 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Swedish Orphan Biovitrum Ab ranks #128 of 1,925 by total payments (top 7% by spend) but spreads that money notably more broadly than its spend rank alone would suggest -- #1,181 of 1,838 by HHI (bottom 36% least concentrated), a wider distribution than most similarly sized payers.
View all 12 companies in this HHI neighborhood as a list
- Kuraray America Inc. : $352.3K total payments, HHI 690
- Ascendis Pharma Inc : $470.4K total payments, HHI 686
- Distalmotion US : $620.2K total payments, HHI 685
- Maxx Orthopedics, Inc. : $96.6K total payments, HHI 683
- Janssen Scientific Affairs, LLC : $5.7M total payments, HHI 681
- Dentsply Sirona Inc : $10.4M total payments, HHI 679
- Swedish Orphan Biovitrum Ab (this company) : $276.4K total payments, HHI 679
- Stereotaxis Inc : $15.7K total payments, HHI 679
- TheracosBio, LLC : $7.4K total payments, HHI 674
- Keystone Dental Inc. : $492.7K total payments, HHI 673
- Roche Diabetes Care, Inc. : $9.1K total payments, HHI 672
- EvoEndo, Inc : $57.2K total payments, HHI 667
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Swedish Orphan Biovitrum Ab's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Swedish Orphan Biovitrum Ab.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Swedish Orphan Biovitrum Ab.
Showing 6 of 1,924 companies with CMS-reported payment data.
Otsuka America Pharmaceutical, Inc.
$14.5M 186,436 recipients
Compare payment profiles
RxSight Inc
$14.5M 7,552 recipients
Compare payment profiles
Roche Diagnostics Operations, Inc.
$14.9M 0 recipients
Compare payment profiles
NovApproach Spine, LLC
$14.5M 178 recipients
Compare payment profiles
Roche Molecular Systems, Inc.
$15.2M 813 recipients
Compare payment profiles
Put this to use
Swedish Orphan Biovitrum Ab ranks #128 of 1,925 by all-tracks total payments, led by "Travel and Lodging".
- See where Swedish Orphan Biovitrum Ab sits among every top spender on the full leaderboard. Top 100 by total payments
- Compare "Travel and Lodging" spend across every manufacturer, not just Swedish Orphan Biovitrum Ab. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.